Intervention Review

You have free access to this content

Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease

  1. Shirley Owusu-Ofori1,*,
  2. Ceri Hirst2

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 31 MAY 2013

Assessed as up-to-date: 19 APR 2013

DOI: 10.1002/14651858.CD003425.pub2


How to Cite

Owusu-Ofori S, Hirst C. Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD003425. DOI: 10.1002/14651858.CD003425.pub2.

Author Information

  1. 1

    Komfo Anokye Teaching Hospital, Transfusion Medicine Unit, Kumasi, Ghana

  2. 2

    Roche, Real World Data Science Site Head, Basel, Switzerland

*Shirley Owusu-Ofori, Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, P.O.Box 1934, Kumasi, Ghana. sowusu_ofori@hotmail.com.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 31 MAY 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. Резюме на простом языке

Background

Acute splenic sequestration crises are a complication of sickle cell disease, with high mortality rates and frequent recurrence in survivors of first attacks. Splenectomy and blood transfusion, with their consequences, are the mainstay of long-term management used in different parts of the world.

Objectives

To assess whether splenectomy (total or partial), to prevent acute splenic sequestration crises in people with sickle cell disease, improved survival and decreased morbidity in people with sickle cell disease, as compared with regular blood transfusions.

Search methods

We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register, which comprises of references identified from comprehensive electronic database searches and handsearching relevant journals and abstract books of conference proceedings.

Additional trials were sought from the reference lists of the trials and reviews identified by the search strategy.

Date of the most recent search: 06 December 2012.

Selection criteria

All randomized or quasi-randomized controlled trials comparing splenectomy (total or partial) to prevent recurrence of acute splenic sequestration crises with no treatment or blood transfusions in people with sickle cell disease.

Data collection and analysis

No trials of splenectomy for acute splenic sequestration were found.

Main results

No trials of splenectomy for acute splenic sequestration were found.

Authors' conclusions

Splenectomy, if full, will prevent further sequestration and if partial, may reduce the recurrence of acute splenic sequestration crises. However, there is a lack of evidence from trials showing that splenectomy improves survival and decreases morbidity in people with sickle cell disease. There is a need for a well-designed, adequately-powered, randomized controlled trial to assess the benefits and risks of splenectomy compared to transfusion programmes, as a means of improving survival and decreasing mortality from acute splenic sequestration in people with sickle cell disease.

There are no trials included in the review and we have not identified any relevant trials up to December 2012. We therefore do not plan to update this review until new trials are published.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. Резюме на простом языке

Removing spleens from people with sickle cell disease after a splenic sequestration compared to blood transfusions to prevent further attacks

In some people with sickle cell disease, red blood cells become trapped and destroyed in the spleen. This damages the spleen, which may become enlarged leading to splenic sequestration crises. These crises consist of abdominal pain, rapid heart rate and other symptoms. Such an attack can be fatal without prompt treatment. All or part of the spleen (splenectomy) is often removed after a person has survived such a crisis to try and prevent another one. This surgery may leave the individual at a higher risk of infection. We looked for trials which compared surgery to blood transfusions. We found no trials to provide reliable evidence about the risks or benefits of splenectomy for people with sickle cell disease after splenic sequestration. There is a need for a trial to assess the benefits and risks of splenectomy compared to transfusion programmes. There are no trials included in the review and we have not identified any relevant trials up to December 2012. We therefore do not plan to update this review until new trials are published.

 

Резюме на простом языке

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. Резюме на простом языке

Сравнение удаления селезенок у людей с серповидно-клеточной анемией (после секвестрации селезенки) с переливанием крови для предотвращения дальнейших атак

У некоторых людей с серповидно-клеточной анемией, красные кровяные клетки задерживаются и разрушаются в селезенке. Это повреждает селезенку, которая может стать увеличенной, что приводит к секвестрационным кризам селезенки. Эти кризы включают в себя боль в животе, учащенное сердцебиение и другие симптомы. Такие атаки могут быть фатальными без незамедлительного лечения. Часто вся или часть селезенки (спленэктомия) удаляется после того, как человек перенес такой криз, чтобы попытаться предотвратить новый криз. Эта операция может может повысить риск инфекций у такого человека. Мы провели поиск испытаний, которые сравнивали операцию с переливаниями крови. Мы не обнаружили испытаний, чтобы привести достоверные доказательства о рисках и пользе спленэктомии для людей с серповидно-клеточной анемией после секвестрации селезенки. Существует необходимость в испытании, чтобы оценить пользу и риски спленэктомии по сравнению с трансфузионными программами. Нет испытаний, включенных в этот обзор и мы не обнаружили каких-либо подходящих испытаний до декабря 2012. Поэтому мы не планируем обновлять этот обзор до публикации новых испытаний.

Заметки по переводу

Заметки по переводу: Перевод: Нурхаметова Диляра Фархадовна. Редактирование: Зиганшина Лилия Евгеньевна. Координация проекта по переводу на русский язык: Казанский федеральный университет - аффилированный центр в Татарстане Северного Кокрейновского Центра. По вопросам, связанным с этим переводом, пожалуйста, обращайтесь к нам по адресу: lezign@gmail.com